WEB予約
LINE予約
AGA
Key takeaway: Finasteride is the “defensive drug that stops hair loss,” while minoxidil is the “offensive drug that promotes regrowth.” Finasteride inhibits 5-alpha reductase type II to suppress DHT production, halting AGA progression in over 90% of patients. Minoxidil shifts hair follicles from the resting (telogen) phase into the growth (anagen) phase, with oral formulations showing roughly 80% regrowth efficacy. Combining the two delivers a synergistic effect, and at our clinic this pairing is recommended as the standard regimen. Compared with monotherapy, clinical research clearly demonstrates faster onset of regrowth and greater overall improvement.
For those who want to know which medication suits them best
Whether finasteride monotherapy, combination therapy, or switching to dutasteride,
our doctors recommend the right prescription based on your AGA progression.
Anyone considering AGA (androgenetic alopecia) treatment will inevitably encounter two medications: finasteride and minoxidil. Both are backed by extensive medical evidence and recommended as first-line therapies in AGA clinical guidelines worldwide. However, these two drugs only appear similar on the surface — their mechanisms of action, efficacy profiles, and side-effect profiles differ substantially. Starting treatment without a proper understanding can lead to disappointing results or unnecessary anxiety.
Drawing on Men’s Care Clinic’s clinical experience and the latest medical literature, this article provides a detailed explanation of the differences, combination effects, and real-world side-effect picture of finasteride and minoxidil. We also cover dutasteride as a third option, along with the philosophy behind the treatment plans we offer.
AGA progresses through two overlapping problems: follicular miniaturization caused by DHT and a shortened hair cycle. Because both must be addressed, the standard approach combines a finasteride-class drug to “stop hair loss” with minoxidil to “promote regrowth.”
Finasteride = the defensive drug: It suppresses production of DHT, the causative substance of AGA, halting progression. It protects existing hair and prevents new shedding. Even as monotherapy, it stops AGA progression in over 90% of patients.
Minoxidil = the offensive drug: It forces hair follicles in the resting (telogen) phase to transition into the growth (anagen) phase, promoting new hair growth. As an approach to recover hair that has already been lost, oral therapy data shows regrowth rates of around 80%.
Finasteride alone can “protect existing hair,” but its power to actively reclaim lost density is limited. Conversely, minoxidil alone can stimulate regrowth, but it does not stop DHT-driven follicular miniaturization, so AGA will eventually outpace its effects. Only by combining both drugs do you achieve the dual goal of “stopping” loss and “growing” hair.
Finasteride is a 5-alpha reductase type II inhibitor approved by the U.S. FDA as an AGA treatment in 1997. In Japan it was approved in 2005 under the brand name Propecia.
The male hormone testosterone is converted into DHT (dihydrotestosterone) by the enzyme 5-alpha reductase type II. When DHT binds to receptors in the hair follicle, the follicle miniaturizes and the hair cycle shortens — the direct cause of AGA. Finasteride selectively inhibits 5-alpha reductase type II and reduces DHT production by approximately 70%.
In a large-scale clinical trial by Kaufman et al. (1998), men who took finasteride 1 mg/day for five years showed AGA progression halted in over 90% of cases, with about 48% achieving moderate to marked improvement. The effect on the vertex was particularly pronounced, and a degree of improvement at the temporal recession (M-shaped) area was also confirmed.
Patients typically notice reduced hair shedding around three months after starting therapy, hair density stabilization at six months, and “maintenance plus mild improvement” by twelve months. Beyond 24 months, continued use sustains the effect and supports long-term hair preservation.
Finasteride monotherapy is well suited for those whose primary goal is preventing progression, those in the early stages of AGA (Hamilton-Norwood II–III), and those who want to keep side-effect risk to a minimum. For more advanced cases (Norwood V or above) or those seeking aggressive regrowth, combination therapy is recommended.
Minoxidil was originally developed as an antihypertensive drug. After the side effect of hypertrichosis was observed in patients, development as a hair-growth medication advanced, and in 1988 it was approved in the United States as a topical hair-growth treatment. Today, both topical and oral formulations are used in AGA treatment.
Minoxidil improves blood flow to dermal papilla cells and promotes the production of follicular growth factors such as VEGF and IGF-1. As a result, follicles in the resting phase are forced into the growth phase and new hair starts to grow. Because it has no DHT-suppressing action, it does not address the root cause of AGA but rather aims to “restart” the follicle.
Topical formulations (Rogaine / Riup, etc.) are applied to the scalp and are a safety-oriented option in which side effects tend to be limited to local reactions such as itching and erythema. Oral formulations circulate systemically through the bloodstream and therefore offer stronger regrowth efficacy, but they carry risks such as palpitations, edema, and generalized hypertrichosis. At our clinic, the doctor evaluates each patient’s overall health and desired level of efficacy before deciding the prescription.
In Olsen et al. (2002), about 60% of AGA patients using 5% topical minoxidil for one year reported clear regrowth improvement. Multiple clinical studies on oral minoxidil have shown perceived regrowth rates of around 80%. However, oral minoxidil is not approved in Japan, so prescription requires careful medical evaluation.
The combination of finasteride and minoxidil is the international gold standard for AGA treatment — the most strongly recommended approach. Multiple clinical studies show that both the speed of perceived regrowth and the overall degree of improvement are significantly superior compared with monotherapy.
Finasteride blocks the “cause of hair loss” while minoxidil flips the “regrowth switch.” This dual approach is known to deliver effects that are multiplicative rather than additive. For patients with moderate to severe AGA in particular, combination therapy is the key to treatment success.
A meta-analysis of multiple clinical trials by Mella et al. (2010) reported that combination therapy increased hair density at roughly 1.5 times the rate of finasteride monotherapy, with markedly higher patient satisfaction as well. At the 12-month mark, the rate of “clear improvement” was about 48% with monotherapy and approximately 72% with combination therapy.
Ideally, combination therapy should begin from the start of treatment for the greatest benefit. Some patients switch from monotherapy to combination after six months, but data show that early combination shortens the lead time to regrowth. The cost burden is higher, but for patients who prioritize the quality and speed of treatment results, we strongly recommend combination therapy.
For those who feel finasteride is not delivering enough effect, or whose AGA is progressing rapidly, dutasteride is a powerful alternative. It can be considered an upgraded version of finasteride.
Whereas finasteride inhibits only type II of 5-alpha reductase, dutasteride inhibits both type I and type II. As a result, its DHT-suppression rate reaches roughly 90% (versus around 70% for finasteride), exerting a stronger anti-DHT action.
If results remain insufficient after more than 12 months on finasteride, switching to dutasteride is considered. Clinical research shows that many patients gain additional improvement in hair volume after switching from finasteride. For rapidly progressing AGA or advanced cases (Hamilton-Norwood V or above), dutasteride is sometimes selected from the outset.
The basic side-effect tendency is similar to finasteride, but because the action is stronger, the frequency of sexual-function-related side effects is reported to be slightly higher. At our clinic, we carefully check for side effects at the initial consultation and at three-month follow-ups while managing the prescription.
When properly understood and used under medical supervision, AGA medications are highly safe treatments. It is also true that online sources contain a great deal of exaggerated side-effect information, so it is essential to make decisions based on accurate data.
The principal side effects are sexual-function-related (decreased libido, reduced erectile function, decreased semen volume), occurring in about 1–2% of large clinical trials. In most cases they resolve after discontinuation. Liver dysfunction has been reported rarely and can be monitored with regular blood tests.
Topical use mainly causes scalp itching, erythema, and temporary initial shedding. Oral use can additionally cause palpitations, edema, dizziness, and generalized hypertrichosis. Because it was originally an antihypertensive, blood pressure and cardiovascular considerations are important. Our clinic exercises particular caution when prescribing for patients with cardiac or renal disease.
It is fundamentally similar to finasteride, but the rate of sexual-function-related side effects is reported to be slightly higher (2–5%). However, individual variation is large, and most patients are able to continue treatment without issue. If side effects become a concern, switching to finasteride or adjusting the dosage is possible.
Finasteride and dutasteride carry a risk of abnormal genital development in male fetuses, so women must not take these drugs and should also avoid handling the tablets. The impact of a man’s own ingestion on his semen is considered limited, but consultation with a doctor is recommended for those planning pregnancy.
At Men’s Care Clinic, we propose individually optimized treatment plans tailored to each patient’s AGA progression, age, lifestyle, and target outcome.
For early- to moderate-stage progression where the main goal is maintenance and preventing further loss. Available from around 10,000 yen per month. Side-effect risk is minimized, making it an entry-level plan that is easy to continue long term.
The standard plan for patients who want active regrowth. Thanks to its strong efficacy, it is the most commonly chosen plan at our clinic. It is ideal for those aiming for clear volume change within 12 months.
An advanced plan for those with rapid progression or insufficient response to finasteride. It maximizes DHT suppression while simultaneously promoting regrowth, and accommodates advanced cases at Hamilton-Norwood V or above.
Both initial and ongoing prescriptions can be completed entirely through online consultations. Patients can be seen from anywhere in Japan, and prescribed medications are shipped to your home — letting you continue AGA treatment without the burden of in-person visits.
AGA TREATMENT
In your free first consultation, we will propose the right medications and combination strategy for your stage of progression.
Online consultations available; nationwide shipping supported.
A. If you want to maximize treatment effect, the ideal is to start both at the same time. If beginning with one, choose finasteride if your goal is to halt AGA progression, or minoxidil if you want active regrowth (noting that minoxidil alone will not stop the cause of hair loss). A doctor will assess your stage of progression and determine the optimal sequence.
A. Because finasteride and minoxidil have different mechanisms of action, there is virtually no overlap of side effects. Each drug’s risk simply exists independently — the side effects are not “amplified” by combining them. We continue treatment while confirming safety through regular consultations and blood tests.
A. Switching is considered when more than 12 months on finasteride still produces insufficient effect, or when AGA progression continues. Because dutasteride suppresses DHT more strongly, additional improvement can be expected for those whose progress has plateaued. However, the side-effect frequency is somewhat higher, so the decision should be made in consultation with your doctor.
A. Oral minoxidil tends to deliver greater regrowth (around 80% perceived regrowth rate vs. roughly 60% for topical). However, oral use carries risks such as palpitations, edema, and generalized hypertrichosis, and is not approved in Japan, so careful medical judgment is required. Those wanting to minimize side-effect risk should choose topical; those seeking maximum efficacy should discuss oral therapy with their doctor.
A. Most side effects improve within several weeks to several months after discontinuation. Sexual-function-related side effects from finasteride and dutasteride also revert to baseline in most patients after stopping. If side effects concern you, do not continue or discontinue on your own — always consult your doctor.
A. Because AGA treatment is classified as cosmetic, in Japan it is not covered by insurance and is paid for entirely out of pocket. However, with the spread of online medical care at many AGA-specialized clinics, prices have come down, and plans available from around 10,000 yen per month have become common.
A. Personal imports without a doctor’s prescription carry high risks of counterfeit medication, contamination, and dosing errors, and are not recommended. Furthermore, if a side effect occurs, you are not eligible for Japan’s pharmaceutical adverse-effect relief system. Cost-wise, online consultations at clinics are not significantly more expensive — for safety and legal protection, receiving a doctor’s prescription is the rational choice.
Reviewed by: Men’s Care Clinic Physician
This article has been reviewed by a physician at Men’s Care Clinic for medical accuracy and conformity to the latest clinical guidelines. It has been written and edited based on the pharmacological evidence and clinical-trial data for AGA medications (finasteride, dutasteride, and minoxidil).
*The contents of this article are general medical information and are not a substitute for individual diagnosis or treatment. For appropriate care of your specific symptoms, please consult a physician at a medical institution.
AGA
関連記事
2021/04/01 AGA 【医師監修】フィナステリドとミノキシジルの違いと併用効果 — AGA治療薬完全ガイド
2021/03/30 AGA 【医師監修】AGA治療いつ生える?発毛経過1年のボリューム変化と効果実感の時期
2021/03/29 AGA 【医師監修】AGA治療は何歳から?20代〜50代の年代別効果と開始時期を解説
2021/03/27 AGA AGA治療は一生続く?服用期間・減薬・費用を医師監修で解説|メンズケアクリニック
2021/03/14 AGA おナニーすると禿げるは嘘|医師が解説する3つの都市伝説と医学的真実
2021/03/13 AGA AGA治療と白髪の関係|治療で白髪は増える?減る?薬別の影響を医師監修で解説
2021/03/03 AGA AGAクリニックのおすすめの選び方5選|失敗しないチェックポイント【医師監修】
2021.04.01
AGA
【医師監修】フィナステリドとミノキシジルの違いと併用効果 — AGA治療薬完全ガイド
2021.03.30
AGA
【医師監修】AGA治療いつ生える?発毛経過1年のボリューム変化と効果実感の時期
2021.03.29
AGA
【医師監修】AGA治療は何歳から?20代〜50代の年代別効果と開始時期を解説
2021.03.27
AGA
AGA治療は一生続く?服用期間・減薬・費用を医師監修で解説|メンズケアクリニック
2021.03.14
AGA
おナニーすると禿げるは嘘|医師が解説する3つの都市伝説と医学的真実
2021.03.13
AGA
AGA治療と白髪の関係|治療で白髪は増える?減る?薬別の影響を医師監修で解説
2021.03.03
AGA
AGAクリニックのおすすめの選び方5選|失敗しないチェックポイント【医師監修】